Navigation Links
New hope for treating Alzheimer's Disease: A role for the FKBP52 protein
Date:3/20/2012

New research in humans published today reveals that the so-called FKBP52 protein may prevent the Tau protein from turning pathogenic. This may prove significant for the development of new Alzheimer's drugs and for detecting the disease before the onset of clinical symptoms.

A study published online today in the Journal of Alzheimer's Disease (1), for the first time demonstrates that the FKBP52 protein, discovered by Prof. Etienne BAULIEU twenty years ago, may prevent hyperphosphorylation of Tau protein, which has been shown to characterise a number of cerebral neurodegenerative diseases, including Alzheimer's Disease (AD).

This work has been carried out by Professor Etienne Baulieu and his research team at Inserm (National Institute for medical research in France) with the support of philanthropists who help the Institut Baulieu, based in France.

Limited research exists on Tau and its role in the development of AD, but it is known that many neurodegenerative diseases are characterised by the deposition of pathological hyperphosphorylated forms of Tau protein, into structures known as 'Tau tangles'. The mechanism of Tau toxicity is unclear and there are currently no drug treatments targeting Tau, nor any biomarkers that predict the risk of a future "Tauopathy". Professor Baulieu decided to focus on Tau abnormalities and was the first to discover in 2010, an interaction between Tau, and the FKBP52 protein (2).

The new research takes his previous research to the next level. It demonstrates a direct correlation between high levels of hyperphosphorylated Tau protein and reduced levels of FKBP52, in brain cells from patients who have died following Alzheimer's Disease, compared with normal brain cells. This suggests that FKBP52 could control the aberrant production of pathogenic Tau. When FKBP52 is reduced in the nerve cells of AD patients, pathogenic Tau is free to accumulate and contribute to the degeneration of brain cell
'/>"/>

Contact: Kristin Shine
KShine@brunswickgroup.com
44-207-404-5959
IOS Press
Source:Eurekalert

Page: 1 2

Related biology news :

1. New approach to treating cystic fibrosis lung infection shows promise
2. Commercial aquatic plants offer cost-effective method for treating wastewater
3. Pitt research identifies new target in brain for treating schizophrenia
4. UC Davis discovery offers hope for treating kidney cancer
5. World breakthrough in treating premature babies
6. Studies point to novel target for treating arrhythmias
7. Antibody key to treating variant CJD, scientists find
8. New medications show promise in treating drug-resistant prostate cancer
9. NC State researchers find soy may aid in treating canine cancers
10. New drug shows promise in treating drug-resistant prostate cancer
11. Cold and brown fat raise the prospect of a new method of treating obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... deep in the primitive brainstem has revealed how we ... School of Medicine and the University at Buffalo School ... second "sleep node" identified in the mammalian brain whose ... produce deep sleep. , Published online in August in ... half of all of the brain,s sleep-promoting activity originates ...
(Date:9/18/2014)... system that can operate inside the bore of an ... a biomedical research partnership program at Brigham and Women,s ... the robot, in conjunction with real-time MRI images, can ... and less discomforting for the patient. The novel system ... with greater precision. , Developed by a team of ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, ... communicating creatures. , But by using a ... radically alter their behavior to suit their population. ... them are present, and act accordingly. , Once ... it may change from innocuous to pathogenic, or ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... 2012 /PRNewswire-iReach/ -- Global Information Inc. is excited ... for Boston, MA in the Spring of 2012. ... April 30 – May 4, 2012 : Cambridge Healthtech Institute ... in Boston, MA. This comprehensive event encompasses 12 tracks, ...
... 14, 2012) A research team has identified epigenetic ... gene expression, within reprogrammed skin cells. These signatures can ... skin cells or induced pluripotent stem cells (iPSCs), cells ... the expression of the protein is controlled brings us ...
... Gutenberg University Mainz (JGU) in Germany have developed a ... the dynamics of proteins is necessary in order to ... molecular level. To date, this information has been obtained ... unfortunately this changes the proteins under investigation and thus ...
Cached Biology News:Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012 2Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012 3Epigenetic signatures direct the repair potential of reprogrammed cells 2Gold nanoantennas detect proteins 2
(Date:9/19/2014)... The new , Healthcare and Life Sciences Review ... PharmaBoardroom.com for free download , looks beyond ... economy in 2009, and the austerity measures that followed, to ... times of trouble. "Despite the crisis, ... and the general conditions to invest are favorable to the ...
(Date:9/18/2014)... 2014 About POCT ... a clinical laboratory. It helps in making fast ... and medication. POCT is gaining popularity due to ... such as diabetes, heart disease, and obesity. It ... standardized to minimize errors during the diagnosis of ...
(Date:9/18/2014)... HARBOR, Mich. , Sept. 18, 2014  Health Enhancement ... biotech firm investigating early-stage algae bioactive compounds and metabolic processes, ... to the company,s board of directors. Ms. Nola E. ... and investment advisor joined the board effective September 17, 2014. ... Ms. Masterson agree to join our board," states Andrew ...
(Date:9/18/2014)... D.C. (PRWEB) September 18, 2014 On ... Durbin and Sen. Jim Risch for National Lab Day ... projects from across the national laboratory system. Durbin and ... which aims to increase awareness of the reach of ... technologies and discoveries to address some of our nation's ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3POCT Market in China 2014-2018 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3
... 2 or 3 patients achieve undetectable HCV RNA levels, following 4 weeks of treatment with ... ... with Pegasys ... plus Copegus -, PRINCETON, N.J., Sept. 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces ...
... Whalen as Solutions Director. , ... ... [Symphony Management Consulting] announced that it has appointed A.J. Whalen ... from Wellesley Information Services (WIS) where he was responsible for ...
... helps visitors to electronica 2008 in Munich and covers topics such ... sources of pre-show information useful in planning a trip, online registration ... an extensive list of web links to travel, hotel, city and ... ...
Cached Biology Technology:Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Symphony Managemnt Consulting Hires New Solutions Director 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 3
... is the most advanced thermal cycler ever ... performance, the Dyad also boasts graphical programming ... navigation via touch pad or mouse. ... economically expanded to a four-bay system with ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... that made the original Gene Pulser apparatus and ... has been applied in the Gene Pulser II ... design of the Gene Pulser II system has ... has the widest range of settings to target ...
... Experion Pro260 reagents and supplies, for ... supplies sufficient to perform protein analysis ... automated electrophoresis system. Supplied are 3 ... microliters Pro260 stain, 60 microliters Pro260 ...
Biology Products: